SLG
LJPC

Stanley-Laman Group’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Stanley-Laman Group’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-156,562
Closed -$4.57M – 243
2018
Q2 		$4.57M Sell
156,562
-11,263
-7% -$348K 1.03% 27
2018
Q1 		$5M Sell
167,825
-828
-0.5% -$26.7K 1.14% 21
2017
Q4 		$5.43M Buy
+168,653
New +$5.51M 1.17% 20

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stanley-Laman Group's LJPC Position: Q3 2018 in Review

Stanley-Laman Group sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2018, closing a stake of 156,562 shares — an estimated $4.57M sold.

Stanley-Laman Group first reported a position in LJPC in Q4 2017 and held it in 3 quarters. The position peaked at $5.43M in Q4 2017. 78 funds tracked by Wall St. Rank hold LJPC as of Q3 2018.

  • Stanley-Laman Group reported no remaining La Jolla Pharmaceutical Company position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 156,562 La Jolla Pharmaceutical Company shares in Q3 2018, an estimated $4.57M.
  • Stanley-Laman Group first reported a position in La Jolla Pharmaceutical Company in Q4 2017 and held it in 3 quarters.
  • Stanley-Laman Group's La Jolla Pharmaceutical Company position peaked at $5.43M in Q4 2017.
  • 78 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.